- Cognivue Amyloid Risk Measure (CARM) estimates the risk of cerebral amyloid deposition in older adults.
- The tool may assist in identifying Alzheimer's disease-related cognitive impairment.
- Integrated into the Cognivue Clarity system, it allows usage in primary care settings without advanced diagnostic tools.
- CARM usage may help reduce unnecessary referrals and prioritize patients for amyloid-lowering therapy.
- The tool was developed and validated in older adults aged 60 to 85 years.
- Study limitations included its cross-sectional design, a limited neuropsychological testing battery, and underrepresentation of certain racial and ethnic populations.
Source: Neurology and Therapy, Cognivue Press
